Umbralisib as a monotherapy in patients with relapsedrefractory marginal zone lymphoma

Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma

11:41 EDT 15 Apr 2019 | ecancermedicalscience

Prof Nathan Fowler speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the use of umbralisib in the treatment of relapsed/refractory marginal zone lymphoma. Prof Fowler reports the findings of this phase II...

More From BioPortfolio on "Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma"